Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease
A legfontosabb adatok
- Ki végzi
- Xuanwu Hospital, Beijing
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 300 fő, tervezett
- Kezdés
- 2026. jún.
- Várható befejezés
- 2029. jan.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Hua Yu Wan Capsule
- Aspirin
- A regiszteradat frissítve
- 2026. június 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with diabetes and early to moderate narrowing of the leg arteries (lower extremity arterial disease). It tests whether Hua Yu Wan Capsule added to standard treatment helps prevent leg pain at rest or foot ulcers.
- Életkor
- 18 to 70 years
- Nem
- All sexes can join
- A betegség stádiuma
- Diabetes plus leg artery disease, Rutherford Classification 2, 3 or 4. Resting ABI ≤ 0.90, or an ABI drop of ≥15% after a treadmill test. Narrowed or blocked leg arteries seen on duplex ultrasound, CTA, MRA or DSA. Must have the TCM pattern of Qi Deficiency and Blood Stasis, checked by a TCM practitioner.
- Korábbi kezelés
- People currently taking anticoagulants (blood thinners such as warfarin, dabigatran, factor Xa inhibitors) cannot join. People using products with Veratrum species cannot join.
- Biomarker vagy leletérték
- HbA1c < 12% (108 mmol/mol). Recent fasting blood glucose < 7.0 mmol/L (126 mg/dL) or blood glucose after meals < 10.0 mmol/L (180 mg/dL). Triglycerides < 1.7 mmol/L (151 mg/dL).
A részvétel fő kizáró okai
- Bleeding disorders or past bleeding in the brain
- Severe heart problems on ECG, or acute coronary syndrome in the last 12 months needing two antiplatelet drugs
- Chronic liver disease (Child-Turcote-Pugh score ≥5) or kidney disease stage 4-5 (eGFR < 30 mL/min/1.73m²)
- Past cancer, except basal cell skin cancer that was fully treated
- Planned leg artery surgery or amputation; pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Aged 18 to 70 years (inclusive), male or female
- Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines
- Glycated hemoglobin (HbA1c) < 12%, with recent fasting blood glucose < 7.0 mmol/L OR postprandial blood glucose < 10.0 mmol/L, and triglycerides < 1.7 mmol/L
- Diagnosed with LEAD, meeting the following criteria:; Rutherford Classification 2, 3, or 4; Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI > 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%; Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA
- TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing "Practical Diagnostic Criteria for Blood Stasis Syndrome" and "Integrated Chinese and Western Medicine Peripheral Vascular Disease"):; Main Symptom: Lower limb weakness, or feeling of heaviness/discomfort after prolonged walking; Secondary Symptoms: Shortness of breath/lassitude in speaking; dry mouth with desire to drink; scaly skin; Tongue \& Pulse: Tongue with teeth marks, pale-purple with petechiae/ecchymosis; thin and choppy pulse; (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)
- Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits
Ki nem vehet részt
- Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors)
- Concurrent or planned use of medicinal products containing Veratrum species
- Currently participating in another drug clinical trial or using therapies with similar purported effects
- Known bleeding disorders or history of intracranial hemorrhage
- Presence of active infection
- History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy
- History of malignancy (except cured basal cell carcinoma)
- Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome
- Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin)
- Patients with psychiatric disorders or judged to be uncooperative
- Any other condition deemed by the investigator to make the participant unsuitable for the trial
- Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval)
- Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR < 30 mL/min/1.73m²)
- Planned lower limb revascularization or amputation
- Pregnant or lactating women, or women of childbearing potential not using highly effective contraception
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
Does adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?
Is the treatment combination safe for participants?
Researchers will compare two groups:
Group 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.
Group 2 (Control): Standard treatment alone.
Participants in this study will:
Be adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).
Be randomly assigned to one of the two treatment groups.
Take their assigned treatment for 6 months.
Attend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.
A vizsgálat 2 csoportja
- Standard Therapy and Hua Yu Wan CapsuleA vizsgált kezelés
1. Standard Baseline Medication: Hua Yu Wan Capsule: 5g, taken orally two times daily. Treatment Duration: The combined regimen is administered continuously for 6 months (divided into four 6-week cycles). 2\. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments without receiving the study drug.
Kezelés: Hua Yu Wan Capsule és Aspirin
- Standard Therapy AloneMár használt kezelés, összehasonlításként
1. Standard Baseline Medication: Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 6 months. 2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments.
Kezelés: Aspirin
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07658807: ki vehet részt
- A regiszteradat frissítve
- 2026. június 22.